Bicara Q2 FY26 net loss widens 102.4% to $55.44 million

Reuters2026/08/11 11:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Bicara posted a Q2 net loss of $55.44 million, more than doubled from a $27.39 million loss a year earlier; loss per share widened to $0.82.
R&D expenses climbed to $45.77 million from $24.8 million, due to costs tied to the FORTIFI-HN01 pivotal trial, Phase 1/1b cohorts, and higher personnel costs.
G&A expenses rose to $14.18 million from $7.22 million, on additional personnel costs and professional fees as it prepares for potential commercialization.
Cash, cash equivalents and marketable securities increased to $497.3 million as of June 30 from $414.8 million at year-end; runway is expected into the first half of 2029.
Ryan Cohlhepp will become CEO on Jan. 1, 2027, while the company targets substantial FORTIFI-HN01 enrollment by year-end and an interim readout in mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110730PRIMZONEFULLFEED9807291) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Bicara Q2 FY26 net loss widens 102.4% to $55.44 million

You may also like

Crypto prices